Interfering with Usp9X function by chemical inhibition through the deubiquitinase inhibitor, WP1130, results in proteasomal degradation of ERG and impaired growth of tumor cells exhibiting this genetic alteration in vivo [34]. This evidence concerns the gene USP9X and neoplasm.